Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1904493rdf:typepubmed:Citationlld:pubmed
pubmed-article:1904493lifeskim:mentionsumls-concept:C0026845lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C0521390lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C0017628lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C1955862lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C0023688lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C1167622lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C1521827lld:lifeskim
pubmed-article:1904493lifeskim:mentionsumls-concept:C1880022lld:lifeskim
pubmed-article:1904493pubmed:issue3lld:pubmed
pubmed-article:1904493pubmed:dateCreated1991-7-12lld:pubmed
pubmed-article:1904493pubmed:abstractTextBinding of the hypoglycemic sulfonylurea, [3H]glyburide, to crude membrane fractions from brain, heart and smooth (intestinal) muscle was saturable, linear with protein concentration and reversible. Saturation analysis revealed high affinity sites (KH values, 7 x 10(-11) M, 5 x 10(-11) M and 6 x 10(-11) M), with Bmax-H values 209, 36 and 23 fmol/mg protein in the brain, heart and smooth muscle, respectively. High affinity [3H]glyburide binding was pharmacologically specific, insensitive to a variety of receptor-active ligands, but sensitive to a series of sulfonylureas, and good, essentially 1:1, correlations were obtained between binding affinities and literature-derived pharmacologic activities. The K+ channel activators, cromakalim, nicorandil, pinacidil and minoxidil were not effective as inhibitors of [3H]glyburide binding. However, diazoxide was a modestly effective inhibitor. Putative low affinity sites (KL values, 3 x 10(-7) M, 1 x 10(-7) M and 2 x 10(-9) M) with Bmax-L values 4956, 336 and 53 fmol/mg protein in brain, heart and smooth muscle, respectively, were identified. Their significance remains to be established. Except for ATP gamma S, the ability of nucleotide triphosphates to inhibit high affinity [3H] glyburide binding was dependent on the presence of Mg++. ADP, in the presence of Mg++, inhibited binding with an IC50 value of 6.3 x 10(-4) M. Nucleotide monophosphates did not inhibit [3H] glyburide binding in the presence or absence of Mg++, whereas in the presence of Mg++, nucleotide triphosphates were equally potent inhibitors of binding. The rank order potency for nucleotide diphosphate inhibition of binding, in the presence of Mg++, is ADP greater than GDP greater than IDP = UDP. In the absence of Mg++, [3H]glyburide binding shows a biphasic response to ADP, and the inhibition of binding by ADP was prevented by ATP. It is suggested that this biphasic response is the result of a second nucleotide binding site.lld:pubmed
pubmed-article:1904493pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:languageenglld:pubmed
pubmed-article:1904493pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:citationSubsetIMlld:pubmed
pubmed-article:1904493pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1904493pubmed:statusMEDLINElld:pubmed
pubmed-article:1904493pubmed:monthJunlld:pubmed
pubmed-article:1904493pubmed:issn0022-3565lld:pubmed
pubmed-article:1904493pubmed:authorpubmed-author:JohnsonD EDElld:pubmed
pubmed-article:1904493pubmed:authorpubmed-author:TriggleD JDJlld:pubmed
pubmed-article:1904493pubmed:authorpubmed-author:JanisR ARAlld:pubmed
pubmed-article:1904493pubmed:authorpubmed-author:Gopalakrishna...lld:pubmed
pubmed-article:1904493pubmed:issnTypePrintlld:pubmed
pubmed-article:1904493pubmed:volume257lld:pubmed
pubmed-article:1904493pubmed:ownerNLMlld:pubmed
pubmed-article:1904493pubmed:authorsCompleteYlld:pubmed
pubmed-article:1904493pubmed:pagination1162-71lld:pubmed
pubmed-article:1904493pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:meshHeadingpubmed-meshheading:1904493-...lld:pubmed
pubmed-article:1904493pubmed:year1991lld:pubmed
pubmed-article:1904493pubmed:articleTitleCharacterization of binding of the ATP-sensitive potassium channel ligand, [3H]glyburide, to neuronal and muscle preparations.lld:pubmed
pubmed-article:1904493pubmed:affiliationDepartment of Biochemical Pharmacology, School of Pharmacy, State University of New York, Buffalo.lld:pubmed
pubmed-article:1904493pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1904493pubmed:publicationTypeIn Vitrolld:pubmed
pubmed-article:1904493pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:1904493lld:pubmed